Абстракт

Цели: To explore the rationale and clinical efficacy of a multimodal treatment strategy in managing corticosteroid-induced rosacea-like dermatitis. Введение: Corticosteroid-induced rosacea-like dermatitis (CIRD) induced by prolonged or inappropriate use of topical corticosteroids presents a therapeutic challenge due to its chronic inflammation, skin barrier disruption, vascular changes and patient hypersensitivity. Multimodal therapy has emerged as an effective approach to address the complex pathophysiology of this condition. Материалы / методы: This approach integrates anti-inflammatory agents, skin barrier repair formulations, vascular changes and microbiome-modulating therapies; including topical anti-inflammatory agents (e.g., calcineurin inhibitors, metronidazole), barrier-repair moisturizers, systemic agents such as low-dose doxycycline and topical probiotics. In addition, vascular-targeted lasers (e.g., pulsed dye laser) and EBDs (e.g., intense pulsed light – IPL) are employed to reduce persistent erythema, telangiectasia, and inflammation. These technologies also contribute to skin rejuvenation and microbiome modulation. Результаты: Multimodal therapy has demonstrated significant improvements in symptom control, reduced flare frequency, and enhanced skin tolerance. Early corticosteroid withdrawal, patient education, and tailored regimens based on disease severity are critical to therapeutic success. Заключение: A comprehensive multimodal treatment strategy offers a safe and effective pathway for managing corticosteroid-induced rosacea-like dermatitis, addressing both symptom relief and long-term skin health restoration.